IL17A and psoriasis: Given the efficacy of secukinumab and other anti-IL17 agents on the skin and musculoskeletal manifestations of psoriatic disease (31–34) and the lack of data on the effect of anti-IL17 on CV risk markers in psoriasis, the CARIMA (Evaluation of cardiovascular risk markers in psoriatic patients treated with secukinumab) study was designed to explore the effects of secukinumab on CV risk markers in patients with psoriasis.